<?xml version="1.0" encoding="UTF-8"?>
<p>With the World Health Organization (WHO) declaring the novel coronavirus outbreak a pandemic 
 <xref rid="onco13306-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="onco13306-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="onco13306-bib-0006" ref-type="ref">6</xref>, focus is needed on the impact of this rapidly spreading viral infection on cancer patients. Patients with cancer are more susceptible to infection than individuals without cancer, because malignancy and anticancer therapy result in an immunosuppressive state 
 <xref rid="onco13306-bib-0007" ref-type="ref">7</xref>. In a retrospective study during the 2009 influenza A (H1N1) virus pandemic, the cancer patient population was at higher incidence of pneumonia (66%) and 30‐day mortality (18.5%) compared with the general population 
 <xref rid="onco13306-bib-0008" ref-type="ref">8</xref>. A recent small case series study that evaluated SARS‐CoV‐2 in cancer patients found that patients with cancer had worse outcomes from SARS‐CoV‐2 than other individuals without cancer 
 <xref rid="onco13306-bib-0007" ref-type="ref">7</xref>.
</p>
